COMPERA / COMPERA-KIDS (COMPERA)
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2023
-
- participants needed
- 12000
-
- sponsor
- Technische Universität Dresden
Summary
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in >50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH.
Since July 2013, also children of any age can be documented (COMPERA-KIDS).
Description
COMPERA will report current and comprehensive data on
- Demographics and clinical course of incident and prevalent PAH and PH patients
- Patient outcomes including survival, by subgroup, by treatment strategy and other factors
- Clinical predictors of short-term and long-term clinical outcomes
- Relationship between PAH medications and patient outcomes
- Temporal trends in treatments and outcomes for newly diagnosed patients
- The state of implementation of current PAH guidelines
- Evolving research needs of the PAH community
- Patients with PAH associated with congenital heart disease and Eisenmenger physiology who do not receive specific drug therapy for PAH ("COMPERA-Eisenmenger", as stated in the amendment dated 23. January 2012).
- Children of any age with PH or PAH (all Dana Point groups), as stated in the amendment dated 1 June 2013 ("COMPERA-KIDS").
Details
| Condition | Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH) |
|---|---|
| Clinical Study Identifier | NCT01347216 |
| Sponsor | Technische Universität Dresden |
| Last Modified on | 25 March 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer